Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Apr 18;201(8):1293–1305. doi: 10.1084/jem.20040912

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2005, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 8. — ChA6 mAb treatment prolongs human islet allograft survival in hu-PBL-NOD/SCID recipient mice. (A) Diabetic NOD/SCID mice were transplanted under the kidney capsule with human islets. Mice were injected intraperitoneally with 50 × 10⁶ allogeneic human PBMCs. Normal NOD/SCID mice (*, n = 8) were used as control of human islets function. Mice were treated with vehicle (•, n = 12); with the Edmonton protocol (♦, n = 4); chA6 mAb at days 0, 3, and 5 after transplantation (▪, n = 14); or sirolimus (▴, n = 3). Glycemia levels monitored graft survival. Asterisks indicate statistical analysis in which treated mice were compared with control mice (*** ≤ 0.0001). (B) Kidney bearing the human-islet graft from control, chA6 mAb–treated, or normal NOD/SCID mice at 100 d after transplantation were snap-frozen, and 5-μm-thick sections were stained with hematoxylin and eosin (HE). Alternatively, sections were stained for the expression of CD3 and insulin.